Skip to main content
. 2016 Nov 26;8(1):1495–1507. doi: 10.18632/oncotarget.13646

Table 3. Results for the nine top-ranked variants after genotyping additional family members in the 75 high-risk families.

SIFT PolyPhen2 Prostate Tissue Final No. Aff No. Unaff Avg Carrier
Chr:Position Variant Prediction - Score Prediction - Score Expressiona No. Fam (n = 372) (n = 238) Frequency (%)b
1:22923859 EPHA8 p.Pro607His Deleterious - 0.02 Benign - 0.432 No 7 17 10 53.7
2:242695399 D2HGDH p.Ala225Thr Deleterious - 0.04 Possibly - 0.774 Yes 9 24 11 40.1
3:97868404 OR5H14 p.Met59Val Deleterious - 0 Probably - 0.994 No 7 12 6 34.9
6:32946119 BRD2 p.Ala605Pro Tolerated - 0.37 Possibly - 0.870 Yes 3 8 1 56.7
17:46805705 HOXB13 p.Gly84Glu Deleterious - 0 Probably - 0.999 Yes 5 11 5 51.3
17:48542714 CHAD p.Ala342Asp Deleterious - 0.02 Possibly - 0.608 Yes 5 13 1 50.4
19:11486354 SWSAP1 p.Leu118Ile Deleterious - 0 Probably - 0.991 Yes 5 11 3 46.0
22:20024596 TANGO2 p.Ser17Ter NAc NAc Yes 3 9 4 63.3
22:50873415 PPP6R2 p.Arg103His Tolerated - 0.17 Probably - 0.977 Yes 3 10 7 64.3
a

Prostate tissue expression were determined using the GTEx Portal (http://www.gtexportal.org/).

b

Supplemental Table S5 has the number of cases with the minor allele and the total number of cases for each segregating family.

c

SIFT and PolyPhen2 do not make predictions for nonsense mutations.